These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 28843656)

  • 1. Disease outcomes in a cohort of women in Ireland infected by hepatitis C-contaminated anti-D immunoglobulin during 1970s.
    Garvey P; Murphy N; Flanagan P; Brennan A; Courtney G; Crosbie O; Crowe J; Hegarty J; Lee J; McIver M; McNulty C; Murray F; Nolan N; O'Farrelly C; Stewart S; Tait M; Norris S; Thornton L
    J Hepatol; 2017 Dec; 67(6):1140-1147. PubMed ID: 28843656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
    Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
    J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in liver histopathology in women infected with hepatitis C through contaminated anti-D immunoglobulin injections in Ireland.
    Albloushi SS; Murray FE; Callagy G; Courtney MG; O'Keane JC; Kay E
    Eur J Gastroenterol Hepatol; 1998 Jan; 10(1):69-73. PubMed ID: 9512956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group.
    Kenny-Walsh E
    N Engl J Med; 1999 Apr; 340(16):1228-33. PubMed ID: 10210705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term follow-up of hepatitis C infection in a large cohort of patients with inherited bleeding disorders.
    Fransen van de Putte DE; Makris M; Fischer K; Yee TT; Kirk L; van Erpecum KJ; Patch D; Posthouwer D; Mauser-Bunschoten EP
    J Hepatol; 2014 Jan; 60(1):39-45. PubMed ID: 23978717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progression of hepatitis C in the haemophiliac population in Ireland, after 30 years of infection in the pre-DAA treatment era.
    Murphy N; O'Mahony B; Flanagan P; Noone D; White B; Bergin C; Norris S; Thornton L;
    Haemophilia; 2017 Sep; 23(5):712-720. PubMed ID: 28752601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study.
    Bellentani S; Pozzato G; Saccoccio G; Crovatto M; Crocè LS; Mazzoran L; Masutti F; Cristianini G; Tiribelli C
    Gut; 1999 Jun; 44(6):874-80. PubMed ID: 10323892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of liver disease progression in the German hepatitis C virus (1b)-contaminated anti-D cohort at 35 years after infection.
    Wiese M; Fischer J; Löbermann M; Göbel U; Grüngreiff K; Güthoff W; Kullig U; Richter F; Schiefke I; Tenckhoff H; Zipprich A; Berg T; Müller T;
    Hepatology; 2014 Jan; 59(1):49-57. PubMed ID: 23929603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of occult hepatitis B virus infection on the outcome of chronic hepatitis C.
    Squadrito G; Cacciola I; Alibrandi A; Pollicino T; Raimondo G
    J Hepatol; 2013 Oct; 59(4):696-700. PubMed ID: 23751755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Projecting severe sequelae of injection-related hepatitis C virus epidemic in the UK. Part 1: Critical hepatitis C and injector data.
    Bird SM; Goldberg DJ; Hutchinson SJ
    J Epidemiol Biostat; 2001; 6(3):243-65; discussion 279-85. PubMed ID: 11437088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural history of hepatitis C virus infection: from chronic hepatitis to cirrhosis, to hepatocellular carcinoma.
    Leone N; Rizzetto M
    Minerva Gastroenterol Dietol; 2005 Mar; 51(1):31-46. PubMed ID: 15756144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy.
    Akuta N; Suzuki F; Hirakawa M; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2011 Jun; 83(6):1016-22. PubMed ID: 21503914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained virological response from interferon-based hepatitis C regimens is associated with reduced risk of extrahepatic manifestations.
    Rossi C; Jeong D; Wong S; McKee G; Butt ZA; Buxton J; Wong J; Darvishian M; Bartlett S; Samji H; Yu A; Binka M; Alvarez M; Adu PA; Tyndall M; Krajden M; Janjua NZ;
    J Hepatol; 2019 Dec; 71(6):1116-1125. PubMed ID: 31433302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proton pump inhibitors are associated with accelerated development of cirrhosis, hepatic decompensation and hepatocellular carcinoma in noncirrhotic patients with chronic hepatitis C infection: results from ERCHIVES.
    Li DK; Yan P; Abou-Samra AB; Chung RT; Butt AA
    Aliment Pharmacol Ther; 2018 Jan; 47(2):246-258. PubMed ID: 29105111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of hepatitis C virus infection in Chinese paid plasma donors: a 12-19-year cohort study.
    Rao HY; Sun DG; Yang RF; Liu F; Wang J; Feng B; Wu N; Fang JL; Song GJ; Ma H; Guo F; Wang JH; Li XB; Jin Q; Qin H; Zhuang H; Wei L
    J Gastroenterol Hepatol; 2012 Mar; 27(3):526-32. PubMed ID: 21871021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Viral eradication reduces all-cause mortality, including non-liver-related disease, in patients with progressive hepatitis C virus-related fibrosis.
    Tada T; Kumada T; Toyoda H; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabatake S; Yama T; Tanaka J
    J Gastroenterol Hepatol; 2017 Mar; 32(3):687-694. PubMed ID: 27577675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of alcohol consumption on the progression of hepatitis C virus infection and risk of hepatocellular carcinoma in Japanese patients.
    Khan KN; Yatsuhashi H
    Alcohol Alcohol; 2000; 35(3):286-95. PubMed ID: 10869250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of antiviral therapy on the course of chronic HCV infection. A systematic review.
    Almasio PL; Venezia G; Craxì A
    Panminerva Med; 2003 Sep; 45(3):175-82. PubMed ID: 14618115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy.
    Shindo M; Ken A; Okuno T
    Cancer; 1999 May; 85(9):1943-50. PubMed ID: 10223234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver fibrosis progression at autopsy in injecting drug users infected by hepatitis C: a longitudinal long-term cohort study.
    Kielland KB; Delaveris GJ; Rogde S; Eide TJ; Amundsen EJ; Dalgard O
    J Hepatol; 2014 Feb; 60(2):260-6. PubMed ID: 24096048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.